4 research outputs found
Processo seletivo de acadêmicos em um curso pré-vestibular popular: relato de experiência sobre o aprimoramento da qualidade de ensino para o vestibulando
No full textO Curso Pré-Vestibular Popular da Faculdade de Medicina de Marília (CP FAMEMA), criado por iniciativa de acadêmicos de medicina, e, posteriormente institucionalizado como programa de extensão, oferece suporte a estudantes em situação de vulnerabilidade socioeconômica para facilitar o acesso ao ensino superior. Considerando-se o método de ensino utilizado na FAMEMA, a Aprendizagem Baseada em Problemas (ABP), o processo seletivo para admissão de membros para os cargos de professor e plantonista do CP FAMEMA foi reformulado e aprimorado. Desse modo, a seleção de professores e plantonistas, que antes era feita através de um sorteio, foi substituída por um processo seletivo que busca avaliar as habilidades pedagógicas e de comunicação do candidato por meio da simulação de um cenário real de ensino, inspirado na metodologia ativa vivenciada na faculdade. Nesse sentido, os candidatos a professores realizam uma aula-teste e os candidatos a plantonistas simulam um plantão de dúvidas. O CP FAMEMA, assim como os demais cursos pré-vestibulares populares, desempenha um papel crucial na democratização do acesso ao ensino superior no Brasil, especialmente para estudantes de camadas marginalizadas. Sendo assim, a institucionalização do programa e as mudanças na seleção possibilitaram mais recursos e melhoria na qualidade de ensino ofertada aos alunos
Estimating and explaining the effect of education and income on head and neck cancer risk : INHANCE consortium pooled analysis of 31 case-control studies from 27 countries
No full text© 2014 UICC.Peer reviewe
The fellowship of St.Diogo : new Christian judaisers in Coimbra in the early 17th century
No full textDr Antonio Homem was a respected teacher in the University of Coimbra, a Canon in the Cathedral and an illustrious scholar. He was also the heir of a long Jewish family tradition. His great-great-grand father lived and died as a Jew. His great-grandfather, his grandmother and two of his uncles were among his relatives to have been sentenced
as judaisers by the Inquisition. His own father kept the Law of Moses, and taught it to all his children, without the knowledge of his wife, an Old Christian of noble lineage.
His concern for the situation of the New Christians in Portugal eventually made him build up a congregation of judaisers, which he called the Fellowship of St Diogo as a tribute to a Capuchin friar who had been executed a few years earlier as an apostate and defender of the Jewish Law. His congregation grew to include over sixty people,
including clerics, physicians, lawyers and students, as well as merchants and farmers. Its leader gave it a corpus of doctrine and eventually a distinctive liturgy, which showed influence from the Catholic Church. The Fellowship also inspired the creation of judaiser conventicles
in three major Monasteries in the Coimbra district, where a relatively large number of nuns held cult meetings and paid homage to Friar Diogo as a martyr of the Law of Moses.
After several years of activity, the Fellowship was investigated and dismantled by the Inquisition. Most of its members were arrested and sentenced. Dr AntOnio Homem was himself taken into custody, charged with heresy and apostasy, as well as sodomy (he was a known paederast), and finally handed over to the secular arm for execution.
His dream of building up a judaiser community in Coimbra was shattered. The Fellowship members who survived either left the country and joined the orthodox Jewish communities in the Netherlands and elsewhere, or stayed in Portugal and gradually lost their Jewish consciousness. Descendants
of some of them can still be found near Coimbra
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
No full textBackground: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics
